SBIR/STTR Research Award

Immune Dampening the OMPs of non-typeable H. influenzae

Award identifier 4499a42fcaa57c2c83d45e717831bf2321be616a5ae958304e07efacdfdb42a9Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$599,999

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIOLOGICAL MIMETICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
LJARDLY9MMK5
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): One of the most challenging aspects of new vaccine development for viruses, bacteria and parasites is overcoming problems of antigenic variation. The development of vaccines against pathogens, which cause otitis media are being vigorously pursued by many groups, but is complicated in a significant way due to their antigenic diversity. Our incomplete understanding of the pathogenic mechanisms used by each of the three major bacterial species (nontypeable Haemophlius influenzae (NTHI), Streptococcus pneumoniae and Moraxella catarrhalis), their viral co-pathogens (Influenza, Rhinovirus, Adenovirus etc) and our inadequate understanding of the pediatric immune response during OM has presented multiple unique challenges. NTHI, a major bacterial pathogen of Otitis Media (OM) in children exhibits considerable strain-to-strain variation. The major outer membrane proteins (OMP) appear to be the major target of serum antibody and important targets of vaccine development. Immunological studies consistently show the antibody is directed to immunodominant, linear epitopes in surface loop structures of the OMPs which are strain dependent, undergo antigenic variation and leave the child unprotected against other circulating NTHI escape variants and strains. Detailed studies of two of these OMPs, the P2 and P5 proteins suggest that some regions of these OMPs exhibit less sequence variation. Thus using selected peptides from this result in the production of more broadly bactericidal antibody following immunization. Immunological and biophysical studies examining surface probability, hydrophilicity, flexibility, and antigenicity plots, strongly suggest that additional, more highly conserved regions of the protein, which are poorly immunogenic under natural conditions, could become immunogenic. Antigenic variation promoted through selective genetic instability is obviously a successful immunological strategy employed by many microbial pathogens. Coupling this to selective and focused immunodominance on the protein structure serves to prevent the immune system from recognizing other antigenic structures on the molecule. These "decoying" epitopes of the OMPs structure results in isolate-, strain- or serotype-specific antibody responses. The host immune system appears fixated on these more visible decoying epitopes at the cost of fully recognizing other conserved and protective epitopes within and between surface protein structures. The objective of this proposal is to further test the technology of immune dampening as a strategy to refocus the immune responses away from immunodominant, non-protective or serotype-restricted epitopes in P2 and P5, towards more broadly protective epitopes which (under natural conditions) are relatively less antigenic. The immune dampened and refocused P2 and P5 will be tested singly and in combination for their ability to induce cross strain protective antibody. Immune dampening technology provides for a new approach to circumventing the issues of antigenic variation and could help into the creation of more broadly protective vaccines against a variety of bacterial, viral and parasitic diseases of man and animals.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

21 SBIR/STTR records share this UEI (2001–2025). Reported award amounts total $15,251,994. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense, Department of Agriculture

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.